Alan Brochstein

Cancer Stocks Hammered Once Again

I don't know the company, but it sure looks interesting. Technically, it would be nice to hold 1.75. The company is seemingly deficient in cash - it would appear that there will be either an equity or debt offering this year. If they become profitable as forecast this year, the stock could get some attention - diagnostics have been hot.

Cancer Stocks Hammered Once Again

Thanks for the comment and the compliment. Thanks also for the information. Contact me by phone or email if you would like to discuss your ideas.

Cancer Stocks Slide Again

I wanted to point out an error in the article - GNVC is developing a pancreatic cancer treatment (not vaccine).

Cancer Stocks Plunge Following ASCO Meeting

Miles, I have a negative bias towards small biotech companies, especially ones like this that have a terrible history of underperforming the stock market, generating losses and diluting with equity issuance. That isn't to say that one might find a diamond in the garbage can, but, I think that one is actually more likely to find a diamond in the garbage can. If one of these companies is creating a truly novel, revolutionary treatment, I personally believe that an investor would have plenty of time to buy later at a higher price and still make a ton of money.

Note, I don't have an opinion specifically on Insmed other than my general observations in the above paragraph.

Cancer Stocks on the Go: Winners and Losers

You get what you pay for, then. If I could publish this list in advance, well, I would be doing it from my boat in the Bahamas!

Many investors look at price action in order to alert them to areas where they should be focused. Is the move overdone (take profits), or is it sustainable (consider buying).